Emyria Limited (ASX:EMD)

Market Cap	46.77M
Revenue (ttm)	1.39M
Net Income (ttm)	-3.14M
Shares Out	806.43M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,792,556
Average Volume	1,820,700
Open	0.0620
Previous Close	0.0620
Day's Range	0.0580 - 0.0620
52-Week Range	0.0210 - 0.0780
Beta	0.13
RSI	51.82
Earnings Date	Feb 26, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.